BGB-A317
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD-1 |
| Identifiers | |
| ChemSpider |
|
BGB-A317 is a humanized monoclonal antibody directed against PD-1.[1] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[1]
It is designed to bind less to Fc gamma receptors.[2]
Clinical trials
Phase I trials began in the US and Australia in June 2015 and are expected to complete in mid-2017.[3] Some early results were announced in July 2016.[4][1]
A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.[2]
Pharmacokinetics
Early phase I clinical trial results give an elimination half-life of 11 to 17 days.[1]
References
- 1 2 3 4 A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. ASCO 2016
- 1 2 BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer. July 2017
- ↑ Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors
- ↑ Early Results of Immunotherapy Study Showing Anti-Cancer Activity in Range of Solid Tumors July 2016
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.